What is the issue size of Senores Pharmaceuticals Ltd IPO?

The issue size of the Senores Pharmaceuticals Ltd IPO is 5821100000.00.

What is 'pre-apply' for Senores Pharmaceuticals Ltd IPO?

Pre-apply will allow you to apply for the Senores Pharmaceuticals Ltd IPO 2 days before the subscription period starts.

If I pre-apply for Senores Pharmaceuticals Ltd IPO, when will my order get placed?

Your order will be placed on the exchange as soon as the Senores Pharmaceuticals Ltd IPO bidding starts. You will receive a UPI request within 24 hours after the bidding period opens.

When will I know if my Senores Pharmaceuticals Ltd IPO order is placed?

We will notify you when your Senores Pharmaceuticals Ltd IPO order is placed with the exchange.

What are the open and close dates of the Senores Pharmaceuticals Ltd IPO?

Senores Pharmaceuticals Ltd IPO will be open between 20 Dec '24 and 24 Dec '24.

What is the lot size and minimum order quantity of the Senores Pharmaceuticals Ltd IPO?

Senores Pharmaceuticals Ltd IPO lot size is 38 and minimum order quantity is 38.

What is the allotment date for the Senores Pharmaceuticals Ltd IPO?

Senores Pharmaceuticals Ltd IPO allotment date is 26 Dec '24. For Senores Pharmaceuticals Ltd IPO allotment status check, you can visit the website of the registrar of the IPO.

Who is the registrar of Senores Pharmaceuticals Ltd IPO?

For Senores Pharmaceuticals Ltd, the IPO registrar is LINK. You can check Senores Pharmaceuticals Ltd IPO allotment status on the website of the registrar.

Where is the Senores Pharmaceuticals Ltd IPO getting listed?

The shares are proposed to be listed on the BSE and NSE.

Senores Pharmaceuticals IPO

Senores Pharmaceuticals Ltd

₹14,136 /38 sharesMinimum Investment

Senores Pharmaceuticals IPO DetailsBidding DatesMin. InvestmentLot SizePrice Range
20 Dec ‘24 - 24 Dec ‘24₹14,13638₹372 - ₹391
Issue SizeIPO Doc
582.11CrRHP PDF
Subscription rateAs of 23 Dec'24, 06:00 PM
Qualified Institutional Buyers0.35x
Non-Institutional Investor24.63x
Retail Individual Investor38.41x
Employees10.14x
Total13.93x
About Senores Pharmaceuticals
Senores Pharmaceuticals is a global pharmaceutical company focused on the development and manufacturing of pharmaceutical products, primarily for regulated markets in the United States, Canada, and the United Kingdom. The company operates across multiple therapeutic areas and dosage forms.
Some of its commercialised products include Acetaminophen Butalbital, Acetaminophen Butalbital Caffeine, Chlorzoxazone, Diclofenac Potassium, Ketorolac, and Mexiletine Hydrochloride. Additionally, Senores Pharmaceuticals also sources specific products from other companies to meet the unique needs of its marketing partners and customers. The company also utilises its Atlanta facility to provide Contract Development and Manufacturing Organisation (CDMO) and Contract Manufacturing Organisation (CMO) services across the US, Canada, and the UK.;Founded in
2017
Managing director
Mr. Swapnil Jatinbhai Shah
Parent organisation
Senores Pharmaceuticals Ltd
Strengths & Financials of Senores PharmaceuticalsStrengths
Risks
Senores has a strong presence in emerging markets, with operations in 43 countries. The company focuses on regions such as Latin America, Africa, the Commonwealth of Independent States (CIS), Southeast Asia, and the Middle East.
The company claims to focus on quality and specialise in identifying complex molecules, resulting in a well-curated pipeline of products across various dosage forms and therapeutic areas. Senores has established partnerships in regulated markets, including the US, Canada, and the UK, with global and Indian pharmaceutical companies like Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Inc., and Cipla USA Inc. 
Senores markets its products in the US, Canada, and the UK through marketing and distribution agreements with pharmaceutical companies. As of September 30, 2024, the company received approvals for 19 ANDAs and has commercialised 21 products in the US and Canadian markets.
By September 30, 2024, Senores had launched 55 products across key therapeutic segments, including antibiotics, antibacterials, antifungals, and blood-related products. The company has a strong presence in hospitals across India, operating through distributor partnerships and direct arrangements with hospitals.
The Chhatral facility can produce four dosage forms: oral solids, oral liquids, injectables, and oral rehydration solutions (ORS). It has dedicated manufacturing areas for Cephalosporins and Beta-Lactam products. 
The Chhatral facility is WHO-GMP approved and is ISO 9001:2015 certified for quality management systems in the development, manufacturing, testing, and marketing of Beta-Lactam oral dosage formulations.
The R&D laboratory at the Chhatral facility is equipped with advanced technology, including 13 high-performance liquid chromatography systems, seven stability chambers, and five auto-dissolution machines. At the Naroda facility, the R&D lab handles various chemical reactions like nitration, bromination, Friedel-Crafts, Grignard, hydrogenation, chlorination, esterification, and hydrolysis. It is equipped with one UV chamber, six fume hoods, and two high-performance liquid chromatography systems.
The company has seen a consistent increase in revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 14.17 crore in FY22 to Rs 35.34 crore in FY23 to Rs 214.52 crore in FY24. PAT increased from Rs 0.99 crore in FY22 to Rs 8.43 crore in FY23 to Rs 32.71 crore in FY24.
Senores Pharmaceuticals Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Senores Pharmaceuticals IPOApply asPrice bandApply upto
Regular₹372 - 391₹2 Lakh
Employee₹372 - 391₹2 Lakh
High Networth Individual₹372 - 391₹2 - 5 Lakh
For Senores Pharmaceuticals IPO, eligible investors can apply as Regular & Employee.

Bidding Dates	Min. Investment	Lot Size	Price Range
20 Dec ‘24 - 24 Dec ‘24	₹14,136	38	₹372 - ₹391

Issue Size	IPO Doc
582.11Cr	RHP PDF

Apply as	Price band	Apply upto
Regular	₹372 - 391	₹2 Lakh
Employee	₹372 - 391	₹2 Lakh
High Networth Individual	₹372 - 391	₹2 - 5 Lakh

Vaishnavi Tech Park, 3rd & 4th Floor
Sarjapur Main Road, Bellandur
Bengaluru – 560103
Contact Us
PRODUCTS
StocksFutures & OptionsMTFIPOMutual FundsNFOETFCreditBill Payments
GROWW
About UsPricingBlogMedia & PressCareersHelp and SupportTrust and Safety
QUICK LINKS
AMC Mutual FundsCalculatorsGlossaryOpen Demat AccountGroww DigestSitemapWeb Stories
ⓒ 2016-2024 Groww. All rights reserved, Built with ♥in India

ABOUT GROWW

Groww is India’s No.1 Stock Broker and Trading Platform with more than 1 crore active customers where users can find their investment solutions pertaining to mutual funds, stocks, US Stocks, ETFs, IPO, and F&Os, to invest their money without hassles.

Groww objectively evaluates stocks and mutual funds and does not advise or recommend any stocks, mutual funds or portfolios. Investors shall invest at their own discretion, will and consent. Groww, at any time, does not guarantee fixed returns on the capital invested.

Groww helps investors -

· By providing 100% paperless online free Demat and trading account opening

· By providing an objective evaluation of products available on the platform

· By being transparent about fees and charges involved while investing in a product

· By offering decision-making assistance by providing technical analysis with advanced charts, well-designed line & candlestick charts that indicate share price movements, and market indices, along with more details about all registered and listed companies

SECURE TRANSACTIONS ON GROWW

All transactions on Groww are safe and secure. Users can invest through SIP or Lumpsum using Netbanking through all supported banks. It uses BSE Star MF (with Member code 11724) as transaction platform.

TRADE AND INVEST SECURELY WITH GROWW

Stocks, Mutual fund investments, F&Os, etc., are very popular with individual investors because of their numerous benefits. On Groww, an investor can -

- Invest in Nifty 50 (NSE) & Sensex (BSE) listed stocks

- Diversify across multiple stocks and other instruments

- Start SIP with any amount (as low as Rs. 500)

- Switch regular funds to direct funds

- Start automated monthly investments (SIP), and benefit from many more features

All type of mutual funds are available on Groww.

INVESTING IN MUTUAL FUND PORTFOLIOS

Portfolio is collection of mutual funds designed to meet your investment goals. Investing in mutual fund portfolios helps you in diversifying your investments and reduces the risk. Portfolios also help you in assigning an investment goals and make it easy for you to save for and achieve your goals. You can create a portfolio yourself or ask an expert to build it for you.

ATTENTION INVESTORS

1. For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors.

2. For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors.

3. KYC is a one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

4. If you are subscribing to an IPO, there is no need to issue a cheque. Please write the Bank account number and sign the IPO application form to authorize your bank to make payment in case of allotment. In case of non allotment the funds will remain in your bank account.

· Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.

· Awareness regarding guidelines on Margin collection

1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Issued in the interest of Investors

DISCLAIMER

Groww Invest Tech Pvt. Ltd. (Formerly known as Nextbillion Technology Pvt. Ltd) (CIN: U65100KA2016PTC092879) is a member of NSE & BSE with SEBI Registration no: INZ000301838, Depository Participant of CDSL Depository with SEBI Registration no: IN-DP-417-2019 and Mutual Fund distributor with AMFI Registration No: ARN-111686. Registered office and Correspondence office - No.11, 2nd floor, 80 FT Road, 4th Block, S.T Bed, Koramangala, Bengaluru – 560034. For any grievances related to Stock Broking/DP, please write to [email protected] , please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.

Groww Invest Tech Pvt. Ltd. (Formerly known as Nextbillion Technology Pvt. Ltd) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Unless otherwise specified, all returns, expense ratio, NAV, etc are historical and for illustrative purposes only. Future will vary greatly and depends on personal and market circumstances. The information provided by our blog is educational only and is not investment or tax advice.

Mutual fund investments are subject to market risks. Please read all scheme related documents carefully before investing. Past performance of the schemes is neither an indicator nor a guarantee of future performance.

Terms and conditions of the website/app are applicable. Privacy policy of the website is applicable.

Qualified Institutional Buyers	0.35x
Non-Institutional Investor	24.63x
Retail Individual Investor	38.41x
Employees	10.14x
Total	13.93x